Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report

Chan, Wan Ying; Ang, Mei‐Kim; Tan, Daniel S.W.; Koh, Wan Lin; Kwek, Jin Wei

doi:10.1016/j.radcr.2016.04.010

Cited by 16 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 It has been suggested only a close laboratory and radiological monitoring are necessary in asymptomatic cysts; although, in rare cases, crizotinib dose reduction or discontinuation is mandatory. 9,12 Here we report the onset of complex renal cysts, perirenal cysts that invaded adjacent structures such as the iliopsoas muscle, and two hepatic cysts during the crizotinib treatment. The local extension of the cysts to adjacent tissues would require percutaneous drainage if the mass effect became clinically relevant.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Mannetta

Carella

Grassadonia

et al. 2020

IMCRJ

View full text Add to dashboard Cite

Background: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. Case Presentation: We herein report the case of a 74-year-old woman who received crizotinib for metastatic ALK-positive NSCLC. During the crizotinib treatment, complex renal cystic lesions with invasion of perirenal spaces and iliopsoas muscle appeared; two complex hepatic cysts were also observed. Almost all lesions disappeared after switching to alectinib, a second-generation ALK inhibitor. Conclusion: It would seem that alectinib is able to reduce in size and number hepatic and renal cysts caused by the crizotinib treatment. Nevertheless, further studies are needed to clarify the role of both crizotinib in the onset of renal and hepatic cysts and alectinib in their disappearance.

show abstract

Section: Discussionmentioning

confidence: 91%

“…6,14,15 A superinfection of crizotinib-induced cysts was reported, so blood cultures were performed to exclude this condition. 11,12 The hepatic cysts had the same radiological aspect as the renal ones, so biopsy had not been deemed necessary to exclude their metastatic nature.…”

Section: Discussionmentioning

confidence: 99%

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Mannetta

Carella

Grassadonia

et al. 2020

IMCRJ

View full text Add to dashboard Cite

show abstract

“…Another case report study showed an individual with anaplastic lymphoma kinase-positive advanced non-small cell pulmonary carcinoma who detected complex kidney cyst during crizotinib therapy. (51). Epidermal growth factor receptor can be bound by ligands that regulate renal inflammation, cell growth, and fibrosis, potentially leading to kidney damage, as summarized by Rayego-Mateos et al (52).…”

Section: Lung Cancer Drugsmentioning

confidence: 99%

Lung cancer and kidney injury: an updated review

et al. 2020

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide, accounting for an estimated 1.8 million deaths. Lung cancer is also the most common primary cancer leading to soft tissue (ST) metastasis. Renal disease may occur as a direct or indirect consequence of the cancer itself (e.g., postrenal obstruction, compression, or infiltration), its treatment (e.g., radiotherapy or chemotherapy), or its related complications (e.g., opportunistic infection). Existing evidence shows that the most frequent primary solid tumor responsible for renal metastasis is pulmonary carcinoma, followed by gastric, breast, soft tissue, and thyroid carcinomas. Chronic kidney disease is a potential risk factor in the survival of patients with lung cancer. In this review, we will discuss causes of kidney injury in relation to lung cancer, potential mechanisms of kidney injury, and treatment options.

show abstract

“…At present, targeted therapy has become one of the most important treatment methods in NSCLC, especially in lung adenocarcinoma with the mutation of driver genes, including c-ros oncogene 1 (ROS1), whose mutation is a rare molecular driver of NSCLC that can be effectively treated with crizotinib ( 3 ). However, crizotinib has been found to have an adverse effect on the development of renal cysts ( 4 , 5 ), with an incidence of 5% showing in the drug instructions. In Asian patients, the incidence of progression of existing renal cysts and the development of new renal cysts are higher in patients who were treated with crizotinib ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Renal Abscess Caused by Crizotinib: A Rare Case Report

et al. 2022

View full text Add to dashboard Cite

Crizotinib is a tyrosine kinase inhibitor that has been found to be effective in the treatment of c-ros oncogene 1-positive non-small cell lung cancer. Although this targeted agent for treating cancer has shown superiority to standard chemotherapy in some ways, this drug has adverse effects, such as the development of renal abscesses. Some associated renal damage may disappear with crizotinib withdrawal. Hence, we present the case of a 58-year-old man with non-small cell lung cancer on crizotinib therapy who developed bilateral renal abnormal space-occupying lesions, successively which were difficult to identify using various imaging methods; even PET-CT highly suspected the right renal masses as malignant. Finally, the right renal lesions were confirmed as renal abscesses by postoperative pathology. The left renal lesion was considered as renal cysts through the lesion disappearing after crizotinib withdrawal. There have been very few reports in this respect, especially proved by various methods and confirmed by postoperative pathology. It is important to recognize this drug-related complication in order to avoid incorrect diagnosis and inadequate therapy. It is necessary to monitor renal changes after taking crizotinib.

show abstract

Imaging features of renal complications after crizotinib treatment for non–small-cell lung cancer: a case report

Cited by 16 publications

References 11 publications

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

<p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>

Lung cancer and kidney injury: an updated review

Renal Abscess Caused by Crizotinib: A Rare Case Report

Contact Info

Product

Resources

About